Isotocyanozene
| Identifiers | |
|---|---|
| |
| Chemical and physical data | |
| Formula | C24H30N4O |
| Molar mass | 390.531 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Isotocyanozene (5-cyano-isotodesnitazene) is a benzimidazole opioid analogue of isotonitazene which has been sold as a designer drug. It was first prospectively observed in a toxicological sample in the Scotland, United Kingdom in 2025, and was presumed to have opioid effects.[1] It has been identified by the drug checking service CanTEST, Australia in September 2025 as an expected 'opioid' sample, and then later as an expected 'benzodiazepine' sample.[2][3] The relative activity of this benzimidazole opioid 'desnitazene' analogue is unknown.
See also
References
- ^ McHenry RD, Dunlop LC, Hudson S, Walters M, Dear JW, Lowe DJ (July 2025). "Isotocyanozene: detection of the 5-cyano analog of isotonitazene in human biological samples". Clinical Toxicology. 63 (9). Philadelphia, Pa.: 691–692. doi:10.1080/15563650.2025.2528990. PMID 40625206.
- ^ CanTEST Health and drug checking service, Canberra (September 2025). "Community Notice 22nd of September 2025: Isotocyanozene found in 'opioid' capsule". Instagram, official account of CanTEST.
{{cite web}}: CS1 maint: multiple names: authors list (link) - ^ "Isotocyanozene found in 'opioid' capsule - The Know". 2025-09-22. Retrieved 2025-09-23.